To develop a lassa fever vaccine
Active Definitive Contract Awarded Last action
- Contract number
- 75N93025C00034
- Awardee
-
Medigen, Inc. UEI MGLJHKGKWBL3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,488,598
Award facts
- Opportunity
-
- 2024 NIAID Omnibus Broad Agency Announcement: "Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases" Solicitation · HHSNIHNIAIDBAA20241 · Posted Dec 13, 2023
- Contract value 100% obligated
- $4,488,598.00 Current and potential, with all options
- Completion date 22% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 27 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Frederick, MD 21701, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $2,307,491 | |
| Other Administrative Action | $0 | |
| Original award | $2,181,107 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $4.488 million definitive contract to Medigen, Inc. for development of a Lassa fever vaccine on September 23, 2025, under cost-no-fee pricing with no set-aside.
Place of performance is Frederick, MD. The originating solicitation, posted December 13, 2023, was a Broad Agency Announcement soliciting proposals for vaccine candidates, therapeutic candidates, and in vitro diagnostics against biodefense and emerging infectious disease threats; the announcement projected award of up to five cost reimbursement contracts totaling approximately $16 million by May 2025. Work extends through September 22, 2030, and includes clinical evaluation of the vaccine candidate through Phase 1 or 2 trials. NAICS codes 541711 and 541712 apply to the underlying research and development in biotechnology and life sciences.
Quick answers
Who was awarded contract 75N93025C00034?
75N93025C00034 was awarded to Medigen, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 23, 2025.
How much is contract 75N93025C00034 worth?
The government has obligated $4,488,598 on 75N93025C00034.
Was contract 75N93025C00034 competed?
The extent of competition for 75N93025C00034 was full and open competition. The government received 27 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award